Pharmacogenomic approach to identify drug sensitivity in small-cell lung Cancer

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Wildey, Gary ^a   Chen, Yanwen ^a   Lent, Ian ^a   Stetson, Lindsay ^a   Pink, John ^a   Barnholtz Sloan, Jill S ^a   Dowlati, Afshin ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 CHLOROANILINO) 4 [2 (3 HYDROXYPROPYLAMINO) 4 PYRIDYL]PYRIMIDINE; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLIN DEPENDENT KINASE; ELESCLOMOL; GW 843682; HEAT SHOCK PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PANOBINOSTAT; POLO LIKE KINASE; POLO LIKE KINASE INHIBITOR; RIGOSERTIB; TOZASERTIB; UNCLASSIFIED DRUG; VOLASERTIB;

ARTICLE; CANCER CELL; CANCER RESEARCH; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG EFFICACY; DRUG SENSITIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; PHARMACOGENOMICS; SMALL CELL LUNG CANCER; CARCINOMA, SMALL CELL; GENETICS; LUNG NEOPLASMS; PHARMACOGENETICS;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS; PHARMACOGENETICS;

EID: 84908702193     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106784     Document Type: Article

References (28)

1. Jackman DM, Johnson BE (2005) Small-Cell lung cancer. The Lancet 366:1385-1396.
2. D'Angelo SP, Pietanza MC (2010) The molecular pathogenesis of small cell lung cancer. Cancer Biology & Therapy 10: 1-10.
3. Hurwitz JL, McCoy F, Scullin P, Fennell DA (2009) New advances in the second-line treatment of small cell lung cancer. The Oncologist 14: 986-994.
4. William WN, Glisson BS (2011) Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol 8: 611-619.
5. Nickolich M, Babakoohi S, Fu P, Dowlati A (2014) Clinical Trial Design in Lung Cancer Small Cell Lung Cancer: Surrogate End Points and Statistical Evolution. Cli 15: 207-212.
6. Janku F, Stewart DJ, Kurzrock R (2010) Targeted therapy in non-small-cell lungcancer- is it becoming a reality? Nature Rev Clin Oncol 7: 401-414.
7. Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer.Lancet Oncol 12: 175-180.
8. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, et al. (2012)Comprehensive genomic analysis identifies SOX2 as a frequently amplified genein small-cell lung cancer. Nat Gen 44: 1111-1116.
9. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, et al. (2012)Integrative genome analyses identify key somatic driver mutations of small-celllung cancer. Nat Gen 44: 1104-1110.
10. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2012)The Cancer Cell Line Encyclopedia enables predictive modeling of anticancedrug sensitivity. Nature 483: 603-607.
11. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, et al. (2012)Systemic identification of genomic markers of drug sensitivity in cancer cells.Nature 483: 570-577.
12. Krzywinski M, Schein J, Birol I, Conners J, Gascoyne R, et al. (2009) Circos: Aninformation aesthetic for comparative genomics. Genome Res 19: 1639-1645.
13. Voortman J, Lee J-H, Killian JK, Suurinirmi M, Wang Y, et al. (2010) Arraycomparative genomic hybridization-based characterization of genetic alterationin pulmonary neuroendocrine tumors. Proc Natl Acad Sci USA 107: 13040-
14. Iwakawa R, Takenaka M, Kohno T, Shimada Y, Totoki Y, et al. (2013)Genome-wide identification of genes with amplification and/or fusion in smallcell lung cancer. Genes Chromosomes Cancer 52: 802-816.
15. Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, et al. (2013)Inconsistency in large pharmacogenomics studies. Nature 504: 389-393.
16. William WN, Glisson BS (2011) Novel strategies for the treatment of small-celllung cancer. Nat Rev Clin Oncol 8: 611-619.
17. Wacker SA, Houghtaling BR, Elemento O, Kampoor TM (2012) Usingtranscriptome sequencing to identify mechanisms of drug action and resistanceNat Chem Biol 8: 235-237.
18. Bredenbeck A, Hollstein VM, Trefzer U, Sterry W, Walden P, et al. (2008)Coordinated expression of clustered cancer/testis genes encoded in a larginverted repeat DNA structure. Gene 415: 68-73.
19. Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, et al. (2013)Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.J Clin Oncol 31: 2388-2395.
20. Karimi S. , Mohammadi F., Porabdollah M., Mohajerani S.A., Khodadad K., et al.Characterization of melanoma-associated antigen-A gene famil differential expression in non-small cell lung cancers. Clin Lung Cancer 13:214-219.
21. Sos ML, Dietlein F, Peifer M, Schöttle J, Balke-Want H, et al. (2012) Aframework for identification of actionable cancer genome dependencies in smallcell lung cancer. Proc Natl Acad Sci USA 109: 17034-17039.
22. De Marinis F, Atmaca A, Tiseo M, Giuffreda L, Rossi A, et al. (2013) A phase IIstudy of the histone deacetylase inhibitor panobinostat (LBH589) in pretreatedpatients with small-cell lung cancer. J Thor Oncol 8: 1091-1094.
23. Gandi L, Chu QS, Stephenson J, Johnson BE, Govindan R, et al. (2009) Anopen label phase II trial of the Plk inhibitor BI 2536, in patients with sensitiverelapse small cell lung cancer (SCLC). J Clin Oncol 27: 15s (suppl, abstr 8108).
24. Jachan NS, Dudley JT, Mazur PK, Flores N, Yang D, et al. (2013) A drugrepositioning approach identifies tricyclic antidepressants as inhibitors of smallcell lung cancer and other neuroendocrine tumors. Cancer Discov 3: 1-14.
25. Beyers LA, Wang J, Nilisson MB, Fujimoto J, Saintigny P, et al. (2012)Proteomic profiling identifies dysregulated pathways in small cell lung cancerand novel therapeutic targets including PARP1. Cancer Discov 2: 798-811.
26. LaBarca C, Paigen K (1980) A simple, rapid, and sensitive DNA assayprocedure. Anal Chem 102: 344-352.
27. Trapnell C, Pachter L, Salzberg SL (2009) Tophat: discovering splice junctionswith RNA-Seq. Bioinformatics 25: 1105-1111.
28. Anders S, Pyl PT, Huber W (2014) HTSeq- A Python framework to work with high-throughput sequencing data. bioR xiv doi: 10.1101/002824